

| | | | |
|--------------------|----------------------|-----------------|-------|
| POLICY NAME | Pyrukynd (mitapivat) | POLICY # | 3167P |
|--------------------|----------------------|-----------------|-------|

Criteria

Hemolytic Anemia related to Pyruvate Kinase Deficiency (PKD)

- ☐ Diagnosis of hemolytic anemia related to Pyruvate Kinase Deficiency (PKD) as evidenced by genetic testing
 - Genetic testing must support at least two mutant alleles of the PKLR gene of which at least one is a missense mutation
- ☐ Age 18 years or older
- ☐ Prescribed by or in consultation with a hematologist (blood disorder doctor) or specialist in hemolytic anemia
- ☐ Patient has required red blood cell transfusions within the last year
- ☐ Hemoglobin level ≤ 10 mg/dL
- ☐ Currently taking folic acid 0.8mg daily

Exclusion Criteria – Any of the following prevents coverage

- ☐ Patients homozygous for the R479H mutation
- ☐ Patients with 2 non-missense mutations in PKLR, without another missense mutation (these patients did not demonstrate benefit from therapy in clinical trials)